NCT01779830

A Study of LY2624803 in Participants With Transient Insomnia

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Crossover Study of Single Doses of LY2624803 in a 5-hour Phase Advance Model of Transient Insomnia in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The aim of this study is to learn how different doses of LY2624803 affect sleep in healthy people. The study has four treatment periods. Participants will receive a single dose of LY2624803, another sleeping pill, or placebo in each treatment period. The study will last approximately 1 month for each participant.

Conditions

• Transient Insomnia

Interventions

Type	Name	Description
DRUG	LY2624803 - Capsules	Administered orally as capsules.
DRUG	Zolpidem - Tablets	Administered orally as tablets.
DRUG	Placebo - Capsules	Administered orally as capsules.
DRUG	Placebo - Tablets	Administered orally as tablets.

Timeline

• Start date: 2008-05-01
• Primary completion: 2008-11-01
• Completion: 2008-11-01
• First posted: 2013-01-30
• Last updated: 2013-01-30

Locations

1 site across 1 country: France